Number of pages: 120 | Report Format: PDF | Published date: 01 March, 2020
Historical Years – 2018 & 2019 | Base Year – 2020 | Forecasted Years – 2021-2031
The global Alzheimer's drugs market was pegged at US$ 4.5 billion in 2020 and is expected to witness a CAGR of 7.2% during the forecast period.
Market Fundamentals
Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills and eventually the ability to carry out the simplest tasks. Alzheimer's is the most common cause of dementia. It accounts for 60-80% of dementia cases. Early-onset Alzheimer's occurs between 30s and mid-60s but is very rare. There's currently no cure for Alzheimer's disease. However, there are medications available that can temporarily reduce the symptoms.
[977345]
Market Dynamics
The global Alzheimer's drugs market is mainly driven by rising prevalence of the Alzheimer's disease, strong product pipeline, growing public and private funding, government initiatives, and increasing awareness programs. Furthermore, increasing number of collaboration and partnership among prominent players is also likely to play a pivotal role in contributing to the growth of the market globally. However, high failure rates of drugs under clinical trials are likely to restrain the market growth to a certain extent.
Market Ecosystem
The global Alzheimer's drugs market has been analyzed from three perspectives: Drug Type, Distribution Channel, and Region.
Alzheimer's Drugs Market by Drug Type
[2132442]
Based on drug type, the Alzheimer's drugs market has been segmented into NMDA receptor antagonists, cholinesterase inhibitors and others (combined drugs, monoclonal antibodies, etc.). The NMDA receptor antagonists segment consists of Memantine drug. Whereas cholinesterase inhibitors consist of Galantamine, Rivastigmine, and Donepezil drugs. The cholinesterase inhibitors segment dominated the market with the largest share in 2020. The growth of the segment can be attributed to the use of cholinesterase inhibitors as a first line treatment for mild to moderate Alzheimer's condition.
Alzheimer's Drugs Market by Distribution Channel
Based on distribution channel, the Alzheimer's drugs market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Online pharmacy segment is anticipated to be the fastest growing distribution channel during the forecast period owing to the rising adoption of online pharmacy in the recent years due to the easy accessibility, discounts provided, and the convenience of home delivery.
Alzheimer's Drugs Market by Region
Based on region, the global Alzheimer's drugs market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the Alzheimer's drugs market, followed by the Asia Pacific. The large share of North America in the global market can be attributed to the rising prevalence of Alzheimer's among geriatric population, rising initiatives by various public and private organizations, and presence of prominent players coupled with large number of drugs present in the pipeline.
Competitive Landscape
Some of the prominent players operating in the Alzheimer's drugs market includes:-
Strategic Developments
Report Attribute |
Details |
Market size value in 2020 |
US$ 4.5 billion |
Revenue forecast in 2031 |
US$ 9.67 billion |
Growth Rate |
CAGR of 7.2% from 2021-2031 |
Base year for estimation |
2020 |
Forecast period |
2021-2031 |
Segments covered |
Drug Type, Distribution Channel, |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global Alzheimer’s drugs Market is expected to clock US$ 4.5 billion in 2020.
The Alzheimer’s drugs market is projected to reach US$ 9.67 billion by 2031
The global Alzheimer’s drugs market is mainly driven by rising prevalence of the Alzheimer’s disease, strong product pipeline, growing public and private funding, government initiatives, and increasing awareness programs.
Daiichi Sankyo Company, Limited, H. Lundbeck A/S, Novartis AG, Lupin Pharmaceuticals, Inc, Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC, AC Immune, F. Hoffmann-La Roche Ltd, Janssen Global Services, LLC, AbbVie Inc
The growth rate of Alzheimer’s drugs market is CAGR of 7.2% between 2021-2031
North America dominated the Alzheimer’s drugs market with the largest share, followed by the Asia Pacific.
*Insights on financial performance is subject to availability of information in public domain
Growth+Reports can now be customized as per client’s needs through GRG Health’s primary research and knowledge services capabilities
GRG Health’s unique GrowthMIX approach and robust research methodology helps us deliver unique & meaningful insights to our clients and uncover trends that won’t meet the standard approach